No Data
No Data
No Data
No Data
No Data
SPAC Swiftmerge to Merge With Cardiac Device Maker HDL Therapeutics
Seeking AlphaAug 12, 2023 03:53
HDL Therapeutics to Go Public in SPAC Deal
By Stephen Nakrosis Biotech company HDL Therapeutics said it would become a publicly-traded company after it agreed to a definitive merger agreement with Swiftmerge Acquisition, a blank check company
Dow JonesAug 12, 2023 02:10
Swiftmerge Acquisition: $480M Combination With HDL Therapeutics to Accelerate Commercialization of Cardiovascular Disease Treatment >IVCP
Swiftmerge Acquisition: $480M Combination With HDL Therapeutics to Accelerate Commercialization of Cardiovascular Disease Treatment >IVCP
Dow JonesAug 12, 2023 01:55
HDL Therapeutics to Go Public in Merger With Swiftmerge Acquisition Corp.
$480 million Business Combination to Accelerate the Commercialization of an Innovative FDA-Approved Cardiovascular Disease Treatment HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held commercial stage
BusinesswireAug 12, 2023 01:54
Swiftmerge Acquisition Corp. Shares To Resume Trade At 12:45 P.m. ET
Swiftmerge Acquisition Corp. Shares To Resume Trade At 12:45 p.m. ET
BenzingaAug 12, 2023 00:26
SPAC Swiftmerge Signs LOI for Potential Merger With HDL Therapeutics
Seeking AlphaApr 27, 2023 03:02
No Data
No Data